Scleroderma - Dhara
Download as PPTX, PDF3 likes625 views
Systemic sclerosis, also known as scleroderma, is an autoimmune disease characterized by fibrosis and vascular abnormalities affecting the skin, joints, and internal organs with symptoms including skin thickening, Raynaud's phenomenon, and gastrointestinal dysfunction. Diagnosis involves clinical criteria and antibody testing, and prognosis varies significantly between limited and diffuse forms, with overall 10-year survival around 65%. Treatment primarily targets symptoms and organ dysfunction, as no drug significantly alters the disease course, though various medications may improve specific manifestations.
Scleroderma - Dhara
- 1. Systemic Sclerosis Dharanidharan Jeyaseelan Group. No 04a 5th Year 1st Semester – June 2019 Tbilisi State Medical University, Georgia
- 2. Scleroderma • Scleroderma is a group of autoimmune diseases that may result in changes to the skin, blood vessels, muscles, and internal organs. • The disease can be either localized to the skin or involve other organs in addition to the skin. • Symptoms may include areas of thickened skin, stiffness, feeling tired, and poor blood flow to the fingers or toes with cold exposure.
- 3. Causes of Scleroderma • The cause is unknown; however, some suspect it may be due to an abnormal immune response. Risk factors include family history, certain genetic factors, and exposure to silica. The underlying mechanism involves the abnormal growth of connective tissue which is believed to occur as a result of the body's immune system attacking healthy tissues. Diagnosis is typically based on a person's symptoms and may be supported by a skin biopsy or blood tests. • Mutations in HLA genes seem to play a crucial role in the pathogenesis of some cases (but not all), likewise silica, aromatic and chlorinated solvents, ketones, trichloroethylene, welding fumes and white spirits exposure seems to contribute to the condition in a small proportion of affected persons.
- 4. Systemic Sclerosis • Systemic sclerosis is a rare chronic disease of unknown cause characterized by diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs (especially the esophagus, lower GI tract, lungs, heart, and kidneys). • Common symptoms include Raynaud phenomenon, polyarthralgia, dysphagia, heartburn, and swelling and eventually skin tightening and contractures of the fingers. • Lung, heart, and kidney involvement accounts for most deaths. • Diagnosis is clinical, but laboratory tests support the diagnosis and aid in prognostication. • Specific treatment is difficult, & emphasis is often on treatment of complications.
- 5. Classification • SSc is classified as • Limited SSc (CREST syndrome) • Generalized SSc (with diffuse skin involvement) • SSc sine scleroderma
- 6. • In limited SSc (CREST syndrome—calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), patients develop skin tightening over the face and distal to the elbows and knees and may also have gastroesophageal reflux disease. This type is characterized by slow progression and is often complicated by pulmonary hypertension. • In generalized SSc with diffuse skin involvement, patients have Raynaud phenomenon and GI complications. This type typically evolves rapidly. Interstitial lung disease and scleroderma renal crisis are the major complications. • In SSc sine scleroderma, patients have SSc-related antibodies and visceral manifestations of the disease but no skin tightening.
- 7. Pathophysiology • Pathophysiology involves vascular damage and activation of fibroblasts; collagen and other extracellular proteins in various tissues are overproduced. • In SSc, the skin develops more compact collagen fibers in the reticular dermis, epidermal thinning, loss of rete pegs, and atrophy of dermal appendages. T cells may accumulate, and extensive fibrosis in the dermal and subcutaneous layers develops. In the nail folds, capillary loops dilate and some microvascular loops are lost. In the extremities, chronic inflammation and fibrosis of the synovial membrane and surfaces and periarticular soft tissues occur. • Esophageal motility becomes impaired, and the lower esophageal sphincter becomes incompetent; gastroesophageal reflux and secondary strictures can develop. The intestinal muscularis mucosa degenerates, leading to pseudodiverticula in the colon and ileum. Interstitial and peribronchial fibrosis or intimal hyperplasia of small pulmonary arteries can develop; if long-standing, pulmonary hypertension can result. Diffuse myocardial fibrosis or cardiac conduction abnormalities occur. Intimal hyperplasia of interlobular and arcuate arteries can develop within the kidneys, causing renal ischemia and hypertension.
- 8. • SSc varies in severity and progression, ranging from generalized skin thickening with rapidly progressive and often fatal visceral involvement (SSc with diffuse scleroderma) to isolated skin involvement (often just the fingers and face) and slow progression (often several decades) before visceral disease develops. • The latter form is termed limited cutaneous scleroderma or CREST syndrome. • In addition, SSc can overlap with other autoimmune rheumatic disorders—eg, sclerodermatomyositis (tight skin and muscle weakness indistinguishable from autoimmune myositis) and mixed connective tissue disease.
- 9. Signs and Symptoms • The most common initial symptoms and signs of systemic sclerosis are Raynaud phenomenon and insidious swelling of the distal extremities with gradual thickening of the skin of the fingers. • Polyarthralgia is also prominent. • GI disturbances (eg, heartburn, dysphagia) or respiratory complaints (eg, dyspnea) are occasionally the first manifestations.
- 10. Skin Manifestations • Swelling of the skin is usually symmetric and progresses to induration. It may be confined to the fingers (sclerodactyly) and hands, or it may affect most or all of the body. • The skin eventually becomes taut, shiny, and hypopigmented or hyperpigmented; the face becomes masklike; and telangiectases may appear on the fingers, chest, face, lips, and tongue. • However, in some patients, skin can soften to variable degrees. • Subcutaneous calcifications may develop, usually on the fingertips (pulps) and over bony eminences. • Digital ulcers are common, especially on the fingertips, overlying the finger joints, or over calcinotic nodules. • Abnormal capillary and microvascular loops in the nails can be seen with an ophthalmoscope or dissecting microscope.
- 11. Joint Manifestation • Polyarthralgias or mild arthritis can be prominent. • Flexion contractures may develop in the fingers, wrists, and elbows. • Friction rubs may develop over the joints, tendon sheaths, and large bursae. Raynaud phenomenon
- 12. GI Manifestation • Esophageal dysfunction is the most frequent visceral disturbance and occurs in most patients. Dysphagia (usually retrosternal) usually develops first. Acid reflux can cause heartburn and stricture. Barrett esophagus occurs in one third of patients and predisposes to complications (eg, stricture, adenocarcinoma). Hypomotility of the small bowel causes bacterial overgrowth that can lead to malabsorption. Air may penetrate the damaged bowel wall and be visible on x-rays (pneumatosis intestinalis). Leakage of bowel contents into the peritoneal cavity can cause peritonitis. Distinctive wide- mouthed diverticula can develop in the colon. Biliary cirrhosis may develop in patients with CREST syndrome.
- 13. Cardiopulmonary Manifestation • Lung involvement generally progresses indolently, with substantial individual variability, but is a common cause of death. • Lung fibrosis and interstitial lung disease are common and can impair gas exchange, leading to exertional dyspnea and restrictive disease with eventual respiratory failure. • Acute alveolitis (potentially responsive to therapy) can develop. • Esophageal dysfunction can lead to aspiration pneumonia. • Pulmonary hypertension may develop, as can heart failure, both of which are poor prognostic findings. • Pericarditis with effusion or pleurisy can occur. • Cardiac arrhythmias are common.
- 14. Renal Manifestation • Severe, often sudden renal disease (scleroderma renal crisis) may occur, most commonly in the first 4 to 5 yr in patients who have diffuse scleroderma and the RNA polymerase III antibody. • It is usually heralded by sudden, severe hypertension with features of thrombotic microangiopathic hemolytic anemia. • It can also occur without acute hypertension or in SSc sine scleroderma, and therefore clinical suspicion is required to make the diagnosis. • Corticosteroid use is a risk factor for development of scleroderma renal crisis.
- 15. Diagnosis • Clinical criteria • Antibody testing • SSc should be considered in patients with Raynaud phenomenon, typical musculoskeletal or skin manifestations, or unexplained dysphagia, malabsorption, pulmonary fibrosis, pulmonary hypertension, cardiomyopathies, or conduction disturbances. • Diagnosis of SSc sine scleroderma should be considered in patients who have unexplained visceral findings. Diagnosis of SSc can be obvious in patients with combinations of classic manifestations, such as Raynaud phenomenon, dysphagia, and tight skin. However, in some patients, the diagnosis cannot be made clinically, and confirmatory laboratory tests can increase the probability of disease but their absence does not exclude it.
- 16. • Antinuclear antibodies (ANA) are present in ≥90%, often with an antinucleolar pattern. Rheumatoid factor is positive in one third of patients. Antibody to centromeric protein (anticentromere antibody) occurs in the serum of a high proportion of patients with limited SSc. • Patients with generalized (diffuse) scleroderma are more likely than those with limited SSc to have anti-Scl-70 (topoisomerase I) antibodies. RNA polymerase III is associated with generalized scleroderma, scleroderma renal crisis, and cancer. U3 RNP (fibrillarin) antibody is also associated with diffuse disease. The most cost-effective way to test for antibodies is to test for ANA, anti-Scl- 70, and anticentromere antibodies first; if results are negative, testing for other antibodies should be considered based on clinical manifestations.
- 17. • To help establish the diagnosis, clinicians can also consult the American College of Rheumatology (ACR)/European League Against Rheumatism's (EULAR) classification criteria for SSc. • ACR/EULAR SSc criteria features include the following: • Skin thickening of the fingers of both hands • Fingertip lesions (eg, ulcers, pitting scars) • Telangiectasia • Abnormal nail fold capillaries (eg, ectatic blood vessels, dropouts) • Pulmonary arterial hypertension and/or interstitial lung disease • Raynaud phenomenon • SSc-related autoantibodies (anticentromere, anti–Scl-70, anti–RNA polymerase III) • These criteria are weighted, in some cases according to subcriteria, and added to generate a score. Scores above a certain threshold are classified as definite SSc.
- 18. Prognosis • The course depends on the type of SSc (generalized vs limited) and antibody profiling but can be unpredictable. Overall 10-yr survival is about 65%. Patients with diffuse skin disease tend to have a more aggressive clinical course and eventually develop visceral complications (usually within the first 3 to 5 yr), which, if severe, can lead to death. Heart failure may be intractable. Ventricular ectopy, even if asymptomatic, increases the risk of sudden death. Patients with limited SSc (CREST syndrome) may have disease that is nonprogressive for long periods; visceral changes (eg, pulmonary hypertension caused by vascular disease of the lung, a peculiar form of biliary cirrhosis) eventually develop, but the course is often remarkably benign.
- 19. Treatment • Treatment directed at symptoms and dysfunctional organs • No drug significantly influences the natural course of SSc overall, but various drugs are of value in treating specific symptoms or organ systems. Corticosteroids may be helpful if there is overt myositis or mixed connective tissue disease but may predispose to renal crisis and thus are used only if necessary. • Various immunosuppressants, including methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide, may help pulmonary alveolitis. Mycophenolate mofetil is effective for the treatment of interstitial lung disease (1) and is the standard of care in some specialized centers. Successful lung transplantation has been reported. Epoprostenol (prostacyclin) and bosentan may be helpful for pulmonary hypertension. • Calcium channel blockers, such as nifedipine 20 mg po tid or as an extended-release formulation, may help Raynaud phenomenon but may worsen gastric reflux. Bosentan, sildenafil, tadalafil, and vardenafil are other alternatives for severe Raynaud phenomenon. Patients should dress warmly, wear mittens, and keep their head warm. IV infusions of prostaglandin E1 (alprostadil) or epoprostenol or sympathetic blockers can be used for digital ischemia.
- 20. • Reflux esophagitis is relieved by frequent small feedings, high- dose proton pump inhibitors, sleeping with the head of the bed elevated, and not lying supine within 3 h of the last meal. Esophageal strictures may require periodic dilation; gastroesophageal reflux may possibly require gastroplasty. Tetracycline 500 mg po bid or another broad-spectrum antibiotic can suppress overgrowth of intestinal flora and may alleviate malabsorption symptoms. • Physiotherapy may help preserve muscle strength but is ineffective in preventing joint contractures. • No treatment has clear benefit in treating calcinosis.
- 21. • For acute renal crisis, a medical emergency, prompt treatment with an ACE inhibitor can dramatically prolong survival. The mortality rate of renal crisis remains high, but the crisis is often reversible if treatment is prompt. Dialysis may be necessary. Renal transplantation is a feasible option in patients who develop end-stage renal disease. • Recent evidence showed that autologous hematopoietic stem cell transplantation in early generalized SSc increases survival after the first year more than does IV cyclophosphamide; however, mortality was higher during the first year. This may become an option in the future for select patients (2). • Some experts encourage periodic screening for pulmonary hypertension with pulmonary function testing and/or echocardiography every 1 to 2 yr, depending on symptoms
- 22. Thank You!